TORONTO, CANADA--(Marketwired - Sept. 17, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced AB569, the Company's drug candidate for treating pulmonary Pseudomonasaeruginosa (P. aeruginosa) infections, has successfully completed pre-clinical in vivo and in vitro validation studies.
In all studies, AB569 has demonstrated significant efficacy against P. aeruginosa. This includes a recent study involving a chronic pulmonary infection model in mice.
The Arch team believes these results provide the scientific rationale for pursuing a human trial to test the safety and efficacy of AB569 for cystic fibrosis (CF) patients whose airways are chronically infected with P. aeruginosa. In this regard, Arch management is currently assessing the appropriate toxicology and regulatory path to the first human trial for AB569.
In the coming months, the scientists involved in the above studies intend to disclose the details of their results in an academic publication.
The Clinical Need for a New Treatment for P. aeruginosa
P. aeruginosa is a significant cause of bacterial respiratory infections in patients who have CF or chronic obstructive pulmonary disease (COPD). It is also a common cause of pneumonia.
There are approximately 40,000 CF patients and over 14 million individuals diagnosed with COPD in the United States. It is estimated that 2 to 3 million people in the USA are diagnosed with pneumonia each year.
In particular, the mucoid form of P. aeruginosa, often found in CF patients, is a very challenging infection to treat due to its high resistance to both antibiotics and phagocyte-mediated killing. Once patients present with the mucoid form of P. aeruginosa, their overall lung function precipitously declines, resulting in a poor prognosis.
Thus, there is an urgent clinical need for the development of novel effective treatments in this area. AB569 constitutes an innovative potential treatment for dealing with mucoid and nonmucoid P. aeruginosa infections that are resistant to traditional antibiotics.
CF is an autosomal recessive genetic disease that causes abnormalities of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is a critical regulator of sweat, digestive fluids, and mucus production.
CF patients are predisposed to lung infections due to abnormal mucus production in the lungs and airways. P. aeruginosa infects 40% of CF patients between the ages of 6 and 10 years of age. By the age of 17, the frequency of infection increases to 60% and reaches approximately 75% of all CF patients between the ages of 25 and 34.
About Arch Biopartners
Arch Biopartners is a portfolio-based biotechnology company established to develop new products and technology for unmet medical needs. The Company's portfolio includes MetaMx, which targets brain tumor initiating cells; ABP569, a new treatment for respiratory P. aeruginosa infections; and, Metablok, a potential treatment for sepsis and cancer metastasis.
Arch has also been developing its peptide-solid surface interface with the objective of reducing corrosion, biofilm formation and improving biocompatibility of various metals and plastics.
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
The Company has 53,189,679 common shares outstanding.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.